shine-logo

News

Home » News

Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical Isotope

SHINE to supply n.c.a. lutetium-177 for the clinical development of [...]

2022-09-20T09:07:05-05:00September 20, 2022|Safer, Healthier, News, News Releases, 2022|

SHINE Submits Drug Master File for n.c.a. Lu-177

SHINE today announced the company has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment.

2022-08-12T09:14:13-05:00July 29, 2022|News, News Releases, 2022|

SHINE CEO to Deliver Keynote at Wisconsin Entrepreneurs’ Conference 

CEO and founder Greg Piefer will give an invited presentation at the Wisconsin Entrepreneurs’ Conference in Milwaukee. On Thursday, June 2 at 8:45 a.m., Piefer will present the opening keynote before engaging in discussion with the audience.  

2022-07-25T12:50:45-05:00May 26, 2022|News, News Releases, 2022|

SHINE Announces Chris Vessell as General Manager of Therapeutics Division

JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

2022-09-08T09:07:21-05:00May 23, 2022|Healthier, News, News Releases, Therapeutics, 2022|

SHINE and U.S. Department of Homeland Security Expand Contraband Detection

SHINE announced it has been awarded a potential 42-month contract with a total funding potential of approximately $16.8 million to help the U.S. Department of Homeland Security (DHS)

2022-04-20T12:42:30-05:00April 20, 2022|News, News Releases, 2022|

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals

2022-09-08T09:10:15-05:00March 9, 2022|Healthier, News, News Releases, Therapeutics, 2022|

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

2022-02-09T20:42:58-06:00February 10, 2022|News, News Releases, 2022|
Go to Top